Sobi to present new data at the ASH 2021 Annual Meeting
/PRNewswire/ -- Sobi™ will present new data at the 63rd Annual Meeting of the American Society of Hematology (ASH) taking place from 11-14 December 2021....
Source: prnewswire.com
Page 4 - Single Arm Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Single Arm Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Single Arm Study Today - Breaking & Trending Today
Sobi to present new data at the ASH 2021 Annual Meeting
STOCKHOLM, Nov. 4, 2021 /PRNewswire/ -- Sobi will present new data at the 63rd Annual Meeting of the American Society of Hematology (ASH) taking place from 11-14 December 2021. Sobi's commitment
Source: finanznachrichten.de
Sobi to present new data at the ASH 2021 Annual Meeting
/PRNewswire/ -- Sobi™ will present new data at the 63rd Annual Meeting of the American Society of Hematology (ASH) taking place from 11-14 December 2021....
Source: prnewswire.com
Late-Breaking Abstracts Announced for the Society for Immunotherapy of Cancer's 36th Annual Meeting
Milwaukee, WI (PRWEB) November 01, 2021 -- The Society for Immunotherapy of Cancer (SITC) received a record-breaking number of abstract submissions in 2021,
Source: prweb.com
Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer
NOVARTIS AG CHF0.50(REGD) Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer Overall survival and radiographic PFS from phase III study of investigational radioligand therapy 177 Lu-PSMA-617 VISION trial of patients with metastatic castration-resistant prostate cancer to be presented at ASCO plenary New Kisqali (ribociclib)* overall survival data from extended follow-up of MONALEESA-3 trial...
Source: investegate.co.uk